The new mRNA-1273.214 vaccine against Covid developed by the American biotech shows a superior neutralizing antibody response one month after administration compared to the original mRNA-1273 vaccine, according to provisional data released by the company, and is expected to be available for next fall, when infections are expected to rebound following the usual seasonal pattern of this and other respiratory viruses.
The new 50-microgram booster dose increased neutralizing antibodies eight-fold among seronegative baseline participants in one study and “met all prespecified endpoints one month after treatment.”
